[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A061202 - A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy

What is the purpose of the study?

This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with refractory multiple myeloma. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop tumor cells from growing. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pomalidomide and dexamethasone are more effective with or without ixazomib in treating multiple myeloma.

Upstate Institutional Review Board (IRB) Number:

946950

Study/Protocol ID:

A061202

Study Phase:

I/II

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

Where will the study take place?

Upstate Cancer Center
Upstate Cancer Center Hematology Oncology at Oswego
Upstate Cancer Center Hematology Oncology at Onieda

ClinicalTrials.Gov ID:

NCT02004275

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Vanessa Gatmaitan
Phone: 315-464-5788
Email: gatmaitv@upstate.edu

Return to Previous Page || Search Again

Top